PIR International is pleased to announce the appointment of Robert (Bob) Radie as Non-Executive Chair and Heather Preston as Advisory Board Member at Monument Therapeutics.
Monument Therapeutics is a neuroscience-focused drug development company headquartered in Manchester, UK. It applies a unique novel drug development strategy, leveraging digital assessments of cognition to select patients suitable for treatment with new innovative drugs.
Bob brings over 30 years of leadership experience in both public and private pharmaceutical and biotech companies. Early in his career at Eli Lilly, he contributed to the successful launch of blockbuster antidepressant and antipsychotic drugs, inspiring his sustained focus on psychiatric and neurological therapeutics. He later drove commercial and acquisition successes at neuroscience small molecule companies Prestwick Pharmaceuticals and Zyla Life Sciences. Bob currently serves as CEO and Chair of nerve injury focused Neuraptive Therapeutics. In addition, he serves on the Boards of biopharmaceutical companies Orcosa and Rockwell Medical (as Chair), as well as ValSource, an employee-owned industry standards company.
Heather Preston, MD, began her career in medicine and management consulting and has over two decades of experience as a healthcare venture capitalist. She has a deep, longstanding interest in developing improved treatments for schizophrenia having served on the Board of Karuna Therapeutics prior to its successful acquisition by Bristol Myers Squibb for $14 billion in 2024.
Bob Radie, Non-Executive Chair of the Board, Monument Therapeutics, said: “I’m delighted to join Monument Therapeutics at such an exciting time in its growth. The company’s precision psychiatry approach has the potential to transform treatment for CNS disorders, and I look forward to supporting the team as we advance the pipeline.”
Dr Jenny Barnett, Chief Executive Officer of Monument Therapeutics, added: “We are thrilled to welcome both Bob and Heather to Monument. Bob’s deep operational experience and successful track record in neuroscience will be invaluable as we scale the company, and Heather’s insight into clinical development and investment strategy strengthens our advisory board at a pivotal moment for our lead programs.”
Click here to read more: Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board